Transdermal nitroglycerin prevents nonsteroidal anti-inflammatory drug gastropathy
Abstract The application of a transdermal nitroglycerin patch (2–30 μg/3 h/rat) protected, in a dose-dependent manner, the rat gastric mucosa against damage induced by the nonsteroidal anti-inflammatory agent indomethacin (20 mg/kg s.c.).
M D, Barrachina +6 more
openaire +3 more sources
Transdermal nitroglycerin as a step 3 antihypertensive drug
The antihypertensive effect of transdermal nitroglycerin was tested in 11 men with hypertension (mean age 60 years) whose diastolic blood pressure exceeded 90 mm Hg while receiving a diuretic and a beta-adrenergic blocker. In a double-blind, randomized crossover trial the subjects received weekly increments of placebo or nitroglycerin (5, 10, 20, and ...
G, Simon, V J, Wittig, J N, Cohn
openaire +3 more sources
Relief of coronary artery spasm by nitroglycerin: Time‐dependent variability in drug action
AbstractThe arteriographic distinction between a fixed atheromatous obstruction and localized vasospasm in the coronary artery is often decided by the response of the lesion to nitroglycerin. We studied the time course of nitroglycerin in four patients with coronary artery spasm as revealed by selective angiography.
E L, Fallen +3 more
openaire +3 more sources
Adhesive Matrix Type Transdermal Drug Delivery System for Nitroglycerin
AbstractThe kinetics of release of nitroglycerin from adhesive matrix type patches was studied. At a high drug to adhesive ratio the patch consisted of nitroglycerin in part dispersed as droplets in the adhesive and in part dissolved in the adhesive.
Rajesh M. Pai +3 more
openaire +2 more sources
Assessment of the Drug Interaction between Intravenous Nitroglycerin and Heparin
OBJECTIVE: To assess whether a clinically significant interaction occurs between heparin and nitroglycerin (NTG). METHODOLOGY: Activated partial thromboplastin time (APTT) was measured in patients with unstable angina who were stabilized on intravenous NTG and heparin just prior to weaning the NTG infusion, and one and four hours after stopping the NTG.
E R, Gonzalez +3 more
openaire +3 more sources
Assessment of the Drug Interaction Between Alteplase and Nitroglycerin: An In Vitro Study
Alteplase is the most commonly administered thrombolytic agent in the United States. However, concurrent therapy with nitroglycerin reduces plasma alteplase concentrations and its clinical efficacy. We sought to determine if this interaction is concentration and pH dependent. Seventy plasma samples were prepared and divided into three groups: alteplase
C M, White +4 more
openaire +3 more sources
Influence of Formulating Factors on Drug Safety of Timed-Release Nitroglycerin Tablets
A peroral sandwich model tablet with timed release, containing proxyphylline and nitroglycerin, was developed. One layer of the tablet constituted the rapidly disintegrating and dissolving initial phase; the other, the depot phase, was in the form of an insoluble, indigestible skeleton.
W. A. Ritschel
openaire +3 more sources
Antianginal drugs. Part II. Human pharmacology of nitroglycerin
Solomon Fisch
openaire +3 more sources
[Influence of the intravenous nitroglycerin dose on the appearance of drug tolerance].
There are few studies on the influence of different doses of intravenous nitroglycerin (NTG) on the appearance of drug tolerance.A controlled clinical trial was performed in 40 patients admitted to an ICU with the diagnosis of acute myocardial infarction (AMI).
F, Barranco +6 more
openaire +2 more sources
The medical treatment of angina pectoris IV. Nitroglycerin as an antianginal drug
Wilbert S. Aronow
openaire +3 more sources

